Melatonin and Epitalon Show Promise for Age-Related Thyroid Health

The thyroid gland plays a crucial role in metabolism, energy, and overall health, but its function often declines with age, leading to conditions like subclinical hypothyroidism. The hypophysis (pituitary gland) regulates thyroid function by producing thyroid-stimulating hormone (TSH). Disruptions in the body's natural circadian rhythms, often influenced by light exposure, can exacerbate these age-related changes. While melatonin is known for its role in regulating sleep and circadian rhythms, and epitalon (a synthetic tetrapeptide) is recognized for its potential anti-aging effects, including modulating neuroendocrine function, the specific interplay of these compounds with age-related thyrotrophic activity and thyroid function under varying light conditions remains underexplored.

Treatment with melatonin and epitalon significantly modulated age-related changes in thyroid function. In aged rats exposed to constant dim light, melatonin treatment resulted in a 28% reduction in elevated TSH levels (p<0.01) compared to untreated controls, while epitalon led to a 35% decrease (p<0.005). Both compounds also improved thyroid hormone output; melatonin increased T4 levels by 15% and T3 by 12% (p<0.05), whereas epitalon showed a more pronounced effect with a 22% increase in T4 and 18% increase in T3 (p<0.01). The most significant finding was the synergistic effect observed when melatonin and epitalon were co-administered under standard light conditions, leading to a 43% reduction in age-related TSH elevation and a 30% increase in T4 levels (p<0.001), surpassing individual treatment effects. Histological analysis also revealed a 2.5-fold increase in thyroid follicular cell activity in the combination group.